This unique on-dose authentication solution combines Hyperion Biosystems' portfolio of physics-based algorithms and AI-enhanced vision systems with Colorcon's custom taggants to add a new level of security to solid oral dose products.
WATERTOWN, Mass. and HARLEYSVILLE, Pa., May 13, 2025 /PRNewswire/ -- Hyperion Biosystems and Colorcon today announced a licensing agreement to commercialize and market a jointly-developed, anti-counterfeiting technology for solid oral dosage pharmaceutical and nutraceutical products. Colorcon is a leading supplier of film coating systems, modified release technology, specialty excipients and functional packaging for the healthcare industry. Hyperion Biosystems applies its deep expertise in optical detection, artificial intelligence (AI) and physics-based algorithms to create solutions for authentication, chemical sensing, product aging, tamper evidence and diagnostics for multiple industries.
"This agreement is the result of a multi-year relationship between Hyperion Biosystems and Colorcon," said Jason Cox, PhD., CEO of Hyperion Biosystems. "Our teams have closely collaborated to create a unique solution for on-dose authentication. By combining our expertise in authentication additives and our core Halo® product suite, we are supporting Colorcon's efforts to solve the highly complex and growing challenge of counterfeit pharmaceutical and nutraceutical products in the global market."
"Colorcon is evaluating various ways to add on-dose authentication technology to its SoteriaRx product portfolio to meet the FDA requirements around physical-chemical identifiers (PCID)," said Gary Pond, Director of Strategic Business Development at Colorcon. "This agreement with Hyperion Biosystems demonstrates our ongoing commitment to customers by offering innovative solutions that will improve security in the pharmaceutical supply chain, seamlessly integrating into existing manufacturing processes and most importantly, safeguarding both patients and trusted brands."
On-dose authentication integrates security measures directly into the dosage form, providing fast product verification and traceability. When products are separated from their original packaging, taggants applied directly within the film coating provides a convenient way for companies to verify whether a product is authentic in markets around the world.
About Hyperion Biosystems
Hyperion Biosystems, a leading provider of advanced sensing technologies, applies its expertise in developing molecular additives, physics-based algorithms, AI-powered vision systems and hardware to design and deliver sophisticated optical detection devices that improve human health and safety. Incubated at MIT and now headquartered in Watertown, MA, Hyperion Biosystems, formerly C2Sense, Inc., was founded to address unmet needs with advanced sensing technologies across industries. For more information about Hyperion Biosystems, visit www.HyperionBiosystems.com.
About Colorcon
Colorcon is a world leader in the development, supply and technical support of formulated film coating systems, modified release technologies, core excipients and functional packaging for the pharmaceutical industry. Colorcon's best-in-class products and technologies are complemented by extensive application data and value-added services to support all phases of solid oral dose including design, development and manufacture. Colorcon's focus on market issues and technology development has earned the company an international reputation as a pharmaceutical supplier of choice. That reputation is based on superior product quality, unparalleled technical support, extensive regulatory assistance and reliable supply from multiple locations. For more information, visit www.colorcon.com.
SOURCE Hyperion Biosystems
Share this article